Back to search results

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

Abroad (travel likely)Recruiting

Conditions

Lymphoma · Leukemia · Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma · Venous Thromboembolic Disease · VTE (Venous Thromboembolism) · PE - Pulmonary Embolism · Hematologic Malignacies

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of Haematology & Transplantology, Gdansk, Pomeranian Voivodeship, Poland

    Contact: Study coordinator (Agata Ogłoza-Puchowska, MD, Principle Investigator) · a.ogloza@gumed.edu.pl · +48 58 584 43 40
    Contact: Study coordinator (Ewa Lewicka, Professor) · e.lewicka@gumed.edu.pl
    Contact: Principal Investigator (Agata Ogłoza-Puchowska, MD)
    Ewa Lewicka, Professor (Sub-investigator)
    Andrzej Mital, Professor (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)